CML-LSCs are recognized as being responsible for resistances and relapses that occur despite the advent of BCR-ABL-targeting therapies with Tyrosine Kinase Inhibitors (TKIs). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.